A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma

Completed

Conditions studied: Colorectal Cancer

In brief

This is an observational study designed to follow patients with metastatic or locally advanced and unresectable colorectal cancer who are receiving Avastin in combination with chemotherapy and whose cancer has been either previously untreated or treated \<=4 months prior to enrollment.

Key facts

Study ID

NCT00097578

Run by

Genentech, Inc.

People needed

1953

Starts

2004-03-01

Expected to finish

2008-07-01

Last updated by the study team

2013-03-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed Informed Consent and Authorization document
• Metastatic, or locally advanced and unresectable, adenocarcinoma of the colon or rectum
• Receiving Avastin as a component of first-line chemotherapy
• First-line chemotherapy plus Avastin initiated <=4 months prior to enrollment in the study

You may not qualify if…

• Patients who have contraindications for treatment with Avastin (see the Avastin Package Insert) or who would incur excessive risks with Avastin treatment are ineligible for this study.

Where it is running

• Genentech Central Contact — South San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.